Document Detail

Eighteen-month clinical safety and efficacy outcomes of sirolimus-, paclitaxel- and zotarolimus-drug eluting stents in diabetic patients undergoing percutaneous coronary intervention for complex coronary artery stenosis.
MedLine Citation:
PMID:  20535428     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: This was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions. MATERIALS AND METHODS: A total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac events (MACE) and stent thrombosis rates. RESULTS: Baseline demographics were comparable among the 3 DES groups (median age was 60 years; 69% men). Complex lesions (defined as ACC/AHA type C stenosis) accounted for 55.6% of the total lesions: SES (50.6%), PES (65.2%) and ZES (43.7%), P = 0.005. At 18 months follow-up, the composite endpoint of MACE was found in 12.7% in SES group, 8.7% in the PES group, 12.7% in ZES group and (P = 0.55). Stent thrombosis (ST) occurred in 1 patient (1.3%) in the SES group, 2 patients (1.4%) in PES group and 1 patient (1.4%) in ZES group, respectively (P = 1.00). CONCLUSION: The use of DES for elective PCI in diabetic patients was associated with favourable intermediate-term clinical outcomes with no significant differences in efficacy among the 3 groups. Stent thrombosis had low event occurrence rate.
Eric Chong; Kian Keong Poh; Shen Liang; Xu Min Hou; Huay Cheem Tan
Related Documents :
11806768 - The proliferation reduction with vascular energy trial (prevent).
16531618 - Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare...
17932898 - Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-elut...
16729398 - Long-term follow up of diabetic patients treated with sirolimus-eluting stents. an angi...
16386628 - Incidence of and risk factors for neurologic complications after heart transplantation.
22748448 - Changing expectations for neurological outcomes after the neonatal arterial switch oper...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Annals of the Academy of Medicine, Singapore     Volume:  39     ISSN:  0304-4602     ISO Abbreviation:  Ann. Acad. Med. Singap.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-06-10     Completed Date:  2010-09-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503289     Medline TA:  Ann Acad Med Singapore     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  381-4     Citation Subset:  IM    
National University Heart Centre, National University Hospital, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Restenosis / prevention & control
Coronary Stenosis / complications,  surgery*
Diabetes Complications*
Drug-Eluting Stents*
Immunosuppressive Agents / administration & dosage*
Middle Aged
Myocardial Infarction
Paclitaxel / administration & dosage*
Sirolimus / administration & dosage*,  analogs & derivatives*
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 0/zotarolimus; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk Factors and Clinical Outcomes for Contrast-induced Nephropathy After Percutaneous Coronary Inte...
Next Document:  Factors affecting the B-type natriuretic Peptide levels in stroke patients.